title: Prognostic value of allelic losses and telomerase activity in meningiomas.
abstract: OBJECTIVE
  The goal of this study was to examine allelic losses and telomerase activity in meningiomas to determine whether they could be used to predict disease recurrence.
  
  
  METHODS
  To identify predictive markers of recurrence, a cohort of high-grade (24 World Health Organization [WHO] Grade II and six WHO Grade III) and low-grade (21 WHO Grade I) meningiomas was investigated for losses of heterozygosity (LOHs) on chromosomes 1p, 9p, 10q, 14q, and 22q, a deletion of CDKN2A, and telomerase activity. Results of molecular analyses were compared with radiological and histological findings and progression-free survival (PFS). Losses of heterozygosity on chromosomes 22q, 1p, and 10q, as well as telomerase activity were related to the WHO histological grades of the lesions (p < 0.01, p < 10(-5), p < 10(-4), and p = 0.002, respectively). In the absence of an LOH on 22q, the other alterations were found infrequently. Overall, the number of molecular alterations was closely related to the histological grades of the lesions (p < 10(-6)). An LOH on 22q occurred much more frequently in convexity or falx (33 [87%] of 38 lesions) than in skull base or spinal meningiomas (four [31%] of 13 lesions) (p < 0.001). The histological grade; Simpson grade; an LOH on chromosome 1p, 9p, or 10q; and telomerase activity were correlated with a shorter PFS time (p < 10(-4), p = 0.02, p = 0.000365, p = 0.022, p = 0.00027, and p = 0.000512, respectively).
  
  
  CONCLUSIONS
  On the basis of these data the authors suggest that LOH analysis and a telomerase activity assay could be useful to determine molecular predictors of outcome in patients with meningiomas.
authors.affiliation: Laboratoire de Biologie des Interactions Neurones-Glie, Institut Nationale de la Santé et de la Recherche Médicale U-495, Service de Neurochirurgie, Fédération de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Leuraud
authors.forename: Edouard
authors.initials: E
authors.lastname: Dezamis
authors.forename: Lucinda
authors.initials: L
authors.lastname: Aguirre-Cruz
authors.forename: Sophie
authors.initials: S
authors.lastname: Taillibert
authors.forename: Julie
authors.initials: J
authors.lastname: Lejeune
authors.forename: Eric
authors.initials: E
authors.lastname: Robin
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Boch
authors.forename: Philippe
authors.initials: P
authors.lastname: Cornu
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002874:Chromosome Mapping; D018450:Disease Progression; D005260:Female; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics*; D008297:Male; D008577:Meningeal Neoplasms / Q000235:genetics*; D008579:Meningioma / Q000235:genetics*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D011237:Predictive Value of Tests; D011379:Prognosis; D019098:Telomerase / Q000235:genetics* / Q000502:physiology
chemical_list: D019098:Telomerase